AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7011353 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin and Ampicillin (both doses)
Number of subjects: 199
Study 31245842 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline screening for high-risk HPV
Number of subjects: 19509
Study 31245842 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HPV negative women
Number of subjects: 19509
Study 31245842 — intervention group
Group type: COMPARATOR
Intervention: Control group (LBC)
Number of subjects: 19509
Study 31245842 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (HPV)
Number of subjects: 19509
Study 31245842 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV negative at exit
Number of subjects: 19509
Study 30859185 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 100 or 200 μg/kg for PSAC; 200, 400 or 600 μg/kg for SAC
Number of subjects: 0
Study 30859185 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (200 μg/kg)
Number of subjects: 0
Study 28422532 — intervention group
Group type: EXPERIMENTAL
Intervention: FP(100) - 100% fast protein
Number of subjects: 31
Study 28422532 — intervention group
Group type: EXPERIMENTAL
Intervention: FP(50) - 50% fast and 50% slow proteins
Number of subjects: 31
Study 28422532 — intervention group
Group type: COMPARATOR
Intervention: FP(20) - 20% fast protein and 80% casein
Number of subjects: 31
Study 23020829 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine iron group (n=2184) received 60 mg of ferrous sulphate plus 400 μg of folic acid daily
Number of subjects: 4326
Study 23020829 — intervention group
Group type: COMPARATOR
Intervention: Selective iron group (n=2142) had screening and treatment for anaemia and a daily intake of 1 mg of folic acid
Number of subjects: 4326
Study 23543344 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 minutes of 120 Hz segmental muscle vibration over the rectus femoris and gastrocnemius medial and lateral, three per week, over a period of four weeks
Number of subjects: 42
Study 23543344 — intervention group
Group type: EXPERIMENTAL
Intervention: botulinum toxin in the rectus femoris, gastrocnemius medial and lateral and soleus, and segmental muscle vibration
Number of subjects: 42
Study 23543344 — intervention group
Group type: COMPARATOR
Intervention: botulinum toxin
Number of subjects: 42
Study 20094773 — intervention group
Group type: EXPERIMENTAL
Intervention: erlotinib 150 mg/day
Number of subjects: 1079
Study 20094773 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1079
Study 20094773 — intervention group
Group type: EXPERIMENTAL
Intervention: erlotinib
Number of subjects: 1079
Study 20031753 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol
Number of subjects: 324
Study 20031753 — intervention group
Group type: COMPARATOR
Intervention: Iomeprol
Number of subjects: 324
Study 20031753 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol (high contrast volume)
Number of subjects: 324
Study 16805715 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab added to chemotherapy
Number of subjects: 0
Study 16805715 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioimmunotherapy
Number of subjects: 0
Study 16805715 — intervention group
Group type: EXPERIMENTAL
Intervention: Stem-cell transplantation
Number of subjects: 0
Study 16827869 — intervention group
Group type: COMPARATOR
Intervention: TAS (tacrolimus/azathioprine/steroids)
Number of subjects: 192
Study 16827869 — intervention group
Group type: EXPERIMENTAL
Intervention: TAS + B (tacrolimus/azathioprine/steroids/basiliximab)
Number of subjects: 192
Study 12810426 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural corticosteroid injections (2 ml prednisolone acetate 50 mg)
Number of subjects: 85
Study 12810426 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (2 ml)
Number of subjects: 85
Study 10198663 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored written information
Number of subjects: 763
Study 10198663 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard written information
Number of subjects: 763
Study 10198663 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 763
Study 7597125 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan depletion (T-)
Number of subjects: 48
Study 7597125 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan enhancement (T+)
Number of subjects: 48
Study 2194466 — intervention group
Group type: EXPERIMENTAL
Intervention: ibuprofen plus a rib belt
Number of subjects: 20
Study 2194466 — intervention group
Group type: COMPARATOR
Intervention: ibuprofen
Number of subjects: 20
Study 7000292 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal treatment (stilboestrol and ethisterone)
Number of subjects: 156
Study 7000292 — intervention group
Group type: COMPARATOR
Intervention: Inactive tablets (control group)
Number of subjects: 156
Study 30541552 — intervention group
Group type: COMPARATOR
Intervention: Low- and middle-income groups
Number of subjects: 14262
Study 30541552 — intervention group
Group type: COMPARATOR
Intervention: Low-income groups
Number of subjects: 14262
Study 30541552 — intervention group
Group type: COMPARATOR
Intervention: High-income groups
Number of subjects: 14262
Study 28074635 — intervention group
Group type: EXPERIMENTAL
Intervention: Active arm participants received pedometers and recorded step counts with physician monitoring and prescriptions; goal was a 3000 steps/day increase over 1 year.
Number of subjects: 347
Study 28074635 — intervention group
Group type: EXPERIMENTAL
Intervention: Active arm participants (not treated with insulin)
Number of subjects: 347
Study 28074635 — intervention group
Group type: COMPARATOR
Intervention: Control arm participants were advised to engage in physical activity 30 to 60 min/day.
Number of subjects: 347
Study 26178653 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal creativity training (20 min per day for 3 weeks)
Number of subjects: 53
Study 26178653 — intervention group
Group type: COMPARATOR
Intervention: Control group (time-delayed training)
Number of subjects: 53
Study 23005579 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intentions (IIs)
Number of subjects: 101
Study 23005579 — intervention group
Group type: COMPARATOR
Intervention: Common intervention activities
Number of subjects: 101
Study 21365308 — intervention group
Group type: EXPERIMENTAL
Intervention: Resonance frequency HRV biofeedback (10 weekly sessions)
Number of subjects: 24
Study 21365308 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24
Study 21365308 — intervention group
Group type: EXPERIMENTAL
Intervention: Resonance frequency HRV biofeedback
Number of subjects: 24
Study 18164106 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-administered quadrivalent HPV-6/11/16/18 L1 VLP and HBV vaccines
Number of subjects: 1877
Study 16879458 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% ropivacaine
Number of subjects: 50
Study 16879458 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 50
Study 12826431 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus platinum chemotherapy
Number of subjects: 802
Study 12826431 — intervention group
Group type: COMPARATOR
Intervention: Conventional platinum-based chemotherapy
Number of subjects: 802
Study 10921706 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose heparin (200 IU/kg)
Number of subjects: 23
Study 10921706 — intervention group
Group type: COMPARATOR
Intervention: Control group (300 IU/kg heparin)
Number of subjects: 23
Study 8888725 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (5.1 g/day)
Number of subjects: 64
Study 8888725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 1796780 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 1,600 micrograms
Number of subjects: 30
Study 1796780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 6138302 — intervention group
Group type: EXPERIMENTAL
Intervention: LH-RH treatment
Number of subjects: 0
Study 6138302 — intervention group
Group type: COMPARATOR
Intervention: HCG treatment
Number of subjects: 0
Study 31416171 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact protein preterm formula (IPF)
Number of subjects: 65
Study 31416171 — intervention group
Group type: COMPARATOR
Intervention: Extensively hydrolyzed formula (EHF)
Number of subjects: 65
Study 28091445 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 3600
Study 28091445 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dexmedetomidine)
Number of subjects: 3600
Study 25640764 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalating reinforcement schedule
Number of subjects: 146
Study 25640764 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed reinforcement schedule
Number of subjects: 146
Study 25640764 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 146
Study 24380609 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 132
Study 24380609 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin
Number of subjects: 132
Study 22639376 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior 90° partial fundoplication
Number of subjects: 79
Study 22639376 — intervention group
Group type: COMPARATOR
Intervention: Nissen fundoplication
Number of subjects: 79
Study 18989343 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% gel
Number of subjects: 40
Study 18989343 — intervention group
Group type: COMPARATOR
Intervention: Tetracaine 1% drops
Number of subjects: 40
Study 17470851 — intervention group
Group type: EXPERIMENTAL
Intervention: FLOX (Fluorouracil 500 mg/m2 IV bolus weekly for 6 weeks + Leucovorin 500 mg/m2 IV weekly for 6 weeks + Oxaliplatin 85 mg/m2 IV on weeks 1, 3, and 5 for three cycles)
Number of subjects: 2407
Study 17470851 — intervention group
Group type: COMPARATOR
Intervention: FULV (Fluorouracil 500 mg/m2 IV bolus weekly for 6 weeks + Leucovorin 500 mg/m2 IV weekly for 6 weeks for three cycles)
Number of subjects: 2407
Study 17470851 — intervention group
Group type: EXPERIMENTAL
Intervention: FLOX
Number of subjects: 2407
Study 17470851 — intervention group
Group type: COMPARATOR
Intervention: FLOX and FULV
Number of subjects: 2407
Study 15472674 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowel preparation with 2 L of polyethylene glycol/electrolyte solution (Group A)
Number of subjects: 80
Study 15472674 — intervention group
Group type: COMPARATOR
Intervention: Clear liquids preparation (Group B)
Number of subjects: 80
Study 11159252 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural block with 7 mL 1% lidocaine
Number of subjects: 30
Study 11159252 — intervention group
Group type: COMPARATOR
Intervention: Epidural injection of an identical volume of normal saline
Number of subjects: 30
Study 11159252 — intervention group
Group type: COMPARATOR
Intervention: IV injection of 1 mg/kg lidocaine
Number of subjects: 30
Study 9355788 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetorphan (oral administration prior to cholera toxin)
Number of subjects: 10
Study 9355788 — intervention group
Group type: COMPARATOR
Intervention: Cholera toxin alone (control group)
Number of subjects: 10
Study 9355788 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetorphan (oral administration)
Number of subjects: 10
Study 9355788 — intervention group
Group type: COMPARATOR
Intervention: Basal conditions (without acetorphan or cholera toxin)
Number of subjects: 10
Study 8297542 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (20 mg/day)
Number of subjects: 2598
Study 8297542 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (40 mg/day)
Number of subjects: 2598
Study 8297542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2598
Study 8297542 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 2598
Study 3443128 — intervention group
Group type: EXPERIMENTAL
Intervention: Molsidomin 8 mg (slow release form)
Number of subjects: 2
Study 3443128 — intervention group
Group type: COMPARATOR
Intervention: ISDN 40 mg (slow release form)
Number of subjects: 2
Study 31246109 — intervention group
Group type: COMPARATOR
Intervention: Mean arterial pressure <70 mmHg
Number of subjects: 657
Study 31246109 — intervention group
Group type: COMPARATOR
Intervention: Mean arterial pressure 70-80 mmHg
Number of subjects: 657
Study 31246109 — intervention group
Group type: COMPARATOR
Intervention: Mean arterial pressure >80 mmHg
Number of subjects: 657
Study 31246109 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivors with impaired cognitive function (n=132, 35%)
Number of subjects: 657
Study 29459229 — intervention group
Group type: EXPERIMENTAL
Intervention: Check & Connect (C&C) intervention for two years
Number of subjects: 345
Study 27641921 — intervention group
Group type: EXPERIMENTAL
Intervention: Midurethral sling surgery (retropubic or transobturator)
Number of subjects: 293
Study 27641921 — intervention group
Group type: EXPERIMENTAL
Intervention: Midurethral sling surgery
Number of subjects: 293
Study 27641921 — intervention group
Group type: EXPERIMENTAL
Intervention: Retropubic sling
Number of subjects: 293
Study 23527517 — intervention group
Group type: EXPERIMENTAL
Intervention: Own-face appearance-based intervention
Number of subjects: 46
Study 23527517 — intervention group
Group type: COMPARATOR
Intervention: Generic appearance-based intervention
Number of subjects: 46
Study 23527517 — intervention group
Group type: COMPARATOR
Intervention: Information-only
Number of subjects: 46
Study 22434058 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid filled intra-uterine extra-amniotic Foley catheter
Number of subjects: 100
Study 22434058 — intervention group
Group type: COMPARATOR
Intervention: 25 microgram misoprostol vaginally every 4 h
Number of subjects: 100
Study 20684724 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of RIX4414
Number of subjects: 475
Study 20684724 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 doses of RIX4414
Number of subjects: 475
Study 20684724 — intervention group
Group type: COMPARATOR
Intervention: 3 doses of placebo
Number of subjects: 475
Study 20684724 — intervention group
Group type: EXPERIMENTAL
Intervention: RIX4414 (2 doses and 3 doses)
Number of subjects: 475
Study 18240018 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback combined with a specific respiratory pattern
Number of subjects: 0
Study 18240018 — intervention group
Group type: COMPARATOR
Intervention: Other respiratory patterns
Number of subjects: 0
Study 15860685 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric knee extensor peak torque
Number of subjects: 27
Study 15860685 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric-slow knee extensor peak torque
Number of subjects: 27
Study 15860685 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadriceps femoris cross-sectional area
Number of subjects: 27
Study 15860685 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg lean mass
Number of subjects: 27
Study 15860685 — intervention group
Group type: EXPERIMENTAL
Intervention: Type I fiber area
Number of subjects: 27
Study 15860685 — intervention group
Group type: EXPERIMENTAL
Intervention: Type IIa fiber area
Number of subjects: 27
Study 15860685 — intervention group
Group type: EXPERIMENTAL
Intervention: Type IIx fiber area
Number of subjects: 27
Study 14522473 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 1018
Study 14522473 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 1018
Study 10999014 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 infusion (1.2 pmol/kg per min)
Number of subjects: 10
Study 10999014 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 10
Study 8820253 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitroglycerin (NTG)
Number of subjects: 10
Study 8820253 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (200 mu g MDI) after NTG
Number of subjects: 10
Study 8820253 — intervention group
Group type: COMPARATOR
Intervention: Inhaled salbutamol (200 mu g MDI) after placebo
Number of subjects: 10
Study 8820253 — intervention group
Group type: COMPARATOR
Intervention: FEV1 after 15 min post-treatment
Number of subjects: 10
Study 2206108 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 20
Study 2206108 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 20
Study 7030121 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine 10 mg
Number of subjects: 100
Study 7030121 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 100
Study 31752370 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum TWK10 (3 × 10^10 CFU)
Number of subjects: 54
Study 31752370 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum TWK10 (9 × 10^10 CFU)
Number of subjects: 54
Study 31752370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 29973970 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen (2 ml of collagen MD Muscle)
Number of subjects: 43
Study 29973970 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (2 ml of 2% lidocaine without a vasoconstrictor)
Number of subjects: 43
Study 29973970 — intervention group
Group type: COMPARATOR
Intervention: Saline (2 ml of 0.9% NaCl)
Number of subjects: 43
Study 27861663 — intervention group
Group type: EXPERIMENTAL
Intervention: β‐TCP plus PRP (study group)
Number of subjects: 18
Study 27861663 — intervention group
Group type: COMPARATOR
Intervention: β‐TCP alone (control group)
Number of subjects: 18
Study 24094754 — intervention group
Group type: EXPERIMENTAL
Intervention: Intoxicating dose of alcohol (.8 g/kg)
Number of subjects: 104
Study 24094754 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 104
Study 22651986 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone case monitoring (TCM)
Number of subjects: 667
Study 22651986 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face continuing care as usual (CCAU)
Number of subjects: 667
Study 20530650 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound plus exercise (group 1, n = 15)
Number of subjects: 45
Study 20530650 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham ultrasound plus exercise (group 2, n = 15)
Number of subjects: 45
Study 20530650 — intervention group
Group type: COMPARATOR
Intervention: No exercise - no treatment (control group, n = 15)
Number of subjects: 45
Study 18826778 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (improved identification, diagnosis, and treatment of depression)
Number of subjects: 145
Study 18826778 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 145
Study 15821692 — intervention group
Group type: EXPERIMENTAL
Intervention: Twin-block (TB) appliance
Number of subjects: 70
Study 15821692 — intervention group
Group type: COMPARATOR
Intervention: mini-block (MB) appliance
Number of subjects: 70
Study 12235695 — intervention group
Group type: EXPERIMENTAL
Intervention: Instillagel
Number of subjects: 59
Study 12235695 — intervention group
Group type: COMPARATOR
Intervention: 2% Lignocainum hydrochloricum (Control)
Number of subjects: 59
Study 10661008 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (50 micrograms twice a day)
Number of subjects: 30
Study 10661008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 8571641 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of dipyridamole prior to PTCA
Number of subjects: 20
Study 8571641 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary dipyridamole infusion during coronary angiography
Number of subjects: 20
Study 8571641 — intervention group
Group type: COMPARATOR
Intervention: Conventional pretreatment
Number of subjects: 20
Study 2300793 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass-ionomer lining cement etched (group A)
Number of subjects: 9
Study 2300793 — intervention group
Group type: COMPARATOR
Intervention: Glass-ionomer lining cement unetched (group B)
Number of subjects: 9
Study 384574 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial hepatic artery infusion with 5-fluorouracil (5-FU)
Number of subjects: 74
Study 384574 — intervention group
Group type: COMPARATOR
Intervention: Systemic chemotherapy with 5-fluorouracil (5-FU)
Number of subjects: 74
Study 6813477 — intervention group
Group type: EXPERIMENTAL
Intervention: Auranofin 2 mg daily
Number of subjects: 0
Study 6813477 — intervention group
Group type: EXPERIMENTAL
Intervention: Auranofin 6 mg daily
Number of subjects: 0
Study 30673750 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent older people (EAT-10 score ≥3)
Number of subjects: 1396
Study 30673750 — intervention group
Group type: EXPERIMENTAL
Intervention: Dependent older people (EAT-10 score ≥3)
Number of subjects: 1396
Study 29733414 — intervention group
Group type: COMPARATOR
Intervention: CON (no supplemental Zn)
Number of subjects: 288
Study 29733414 — intervention group
Group type: EXPERIMENTAL
Intervention: ZnAA0 (60 mg Zn/kg from ZnSO4)
Number of subjects: 288
Study 29733414 — intervention group
Group type: EXPERIMENTAL
Intervention: ZnAA60 (60 mg Zn/kg from ZnAA)
Number of subjects: 288
Study 29733414 — intervention group
Group type: EXPERIMENTAL
Intervention: ZnAA90 (90 mg Zn/kg from ZnAA)
Number of subjects: 288
Study 29733414 — intervention group
Group type: EXPERIMENTAL
Intervention: ZnAA120 (120 mg Zn/kg from ZnAA)
Number of subjects: 288
Study 29733414 — intervention group
Group type: EXPERIMENTAL
Intervention: ZnAA150 (150 mg Zn/kg from ZnAA)
Number of subjects: 288
Study 29733414 — intervention group
Group type: EXPERIMENTAL
Intervention: All ZnAA treatments (ZnAA0, ZnAA60, ZnAA90, ZnAA120, ZnAA150)
Number of subjects: 288
Study 26562367 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (discontinued)
Number of subjects: 50
Study 25319764 — intervention group
Group type: EXPERIMENTAL
Intervention: CareToy training for four weeks, customized by rehabilitation staff.
Number of subjects: 40
Study 25319764 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 40
Study 22222634 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel (4 mg/d)
Number of subjects: 723
Study 22222634 — intervention group
Group type: EXPERIMENTAL
Intervention: Entacapone (200 mg with each dose of L-dopa)
Number of subjects: 723
Study 22222634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 723
Study 20574018 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.45% OT-551 administered three times daily for 2 years
Number of subjects: 10